Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul N Durrington

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Diabetes Care|May 28, 2005
Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populationsJeetesh V Patel, Avni Vyas, Dorairaj Prabhakaran, et al.
Frontiers in Cardiovascular Medicine|August 22, 2024
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemiaBilal Bashir, Jonathan Schofield, Paul Downie, et al.
Human & Experimental Toxicology|December 23, 2003
Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposureAntonio F Hernández, Bharti Mackness, Lourdes Rodrigo, et al.
Clinical Endocrinology|December 8, 2004
Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapySee Kwok, Peter L Selby, Patrick McElduff, et al.
Diabetes Care|October 27, 2006
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)H Andrew W Neil, David A DeMicco, Don Luo, et al.
Diabetologia|November 19, 2015
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)Shona J Livingstone, Helen C Looker, Tahira Akbar, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 23, 2009
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)Helen M Colhoun, D John Betteridge, Paul N Durrington, et al.
Diabetes & Vascular Disease Research|September 9, 2008
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)Connie B Newman, Michael Szarek, Helen M Colhoun, et al.
Atherosclerosis|May 25, 2018
Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetesMarco Colombo, Helen C Looker, Bassam Farran, et al.
Journal of Clinical Lipidology|December 17, 2017
A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trialHandrean Soran, Yifen Liu, Safwaan Adam, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Diabetes Care|May 28, 2005
Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populationsJeetesh V Patel, Avni Vyas, Dorairaj Prabhakaran, et al.
Frontiers in Cardiovascular Medicine|August 22, 2024
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemiaBilal Bashir, Jonathan Schofield, Paul Downie, et al.
Human & Experimental Toxicology|December 23, 2003
Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposureAntonio F Hernández, Bharti Mackness, Lourdes Rodrigo, et al.
Clinical Endocrinology|December 8, 2004
Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapySee Kwok, Peter L Selby, Patrick McElduff, et al.
Diabetes Care|October 27, 2006
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)H Andrew W Neil, David A DeMicco, Don Luo, et al.
Diabetologia|November 19, 2015
Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)Shona J Livingstone, Helen C Looker, Tahira Akbar, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 23, 2009
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)Helen M Colhoun, D John Betteridge, Paul N Durrington, et al.
Diabetes & Vascular Disease Research|September 9, 2008
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)Connie B Newman, Michael Szarek, Helen M Colhoun, et al.
Atherosclerosis|May 25, 2018
Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetesMarco Colombo, Helen C Looker, Bassam Farran, et al.
Journal of Clinical Lipidology|December 17, 2017
A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trialHandrean Soran, Yifen Liu, Safwaan Adam, et al.
Pageof 11